Justin Zelin analyst BTIG

Currently out of the existing stock ratings of Justin Zelin, 35 are a BUY (97.22%), 1 are a HOLD (2.78%).

Justin Zelin

Work Performance Price Targets & Ratings Chart

Analyst Justin Zelin works at BTIG with a stock forecast success ratio of 25.69% fulfilled within 104.58 days on average.

Justin Zelin’s has documented 69 price targets and ratings displayed on 14 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on VKTX, Viking Therapeutics at 26-Mar-2024.

Wall Street Analyst Justin Zelin

Analyst best performing recommendations are on ABEO (ABEONA THERAPEUTICS).
The best stock recommendation documented was for ABEO (ABEONA THERAPEUTICS) at 11/11/2020. The price target of $75 was fulfilled within 89 days with a profit of $42.5 (130.77%) receiving and performance score of 14.69.

Average potential price target upside

ABEO Abeona Therapeutics ACET Adicet Bio BLU BELLUS Health . LEGN Legend Biotech Corp MBIO Mustang Bio CASI CASI Pharmaceuticals PSTX Poseida Therapeutics SURF Surface Oncology MEIP MEI Pharma VKTX Viking Therapeutics ETN Eaton PLC ETNB 89bio IMCR Immunocore Holdings Ltd GRCL Gracell Biotechnologies .

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$-1.52 (-20.21%)


1 years 4 months 29 days ago

2/3 (66.67%)

$1.85 (44.58%)




1 years 5 months 4 days ago

1/2 (50%)

$10.34 (221.89%)



2 years 4 months 14 days ago

0/1 (0%)

$332.5 (79.64%)



$70.79 (1681.47%)


3 years 5 months 1 days ago

2/3 (66.67%)

$45.92 (117.11%)




3 years 11 months 4 days ago

1/3 (33.33%)

$-59.25 (-72.92%)


Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Justin Zelin is most bullish on?

Potential upside of $49.12 has been obtained for VKTX (VIKING THERAPEUTICS)

Which stock is Justin Zelin is most reserved on?

Potential downside of -$0 has been obtained for GRCL (GRACELL BIOTECHNOLOGIES .)

What Year was the first public recommendation made by Justin Zelin?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?